Incanthera PLC (AQSE:INC) said it expects to generate revenues of £10 million next financial year, and, crucially, be profitable as it announced a significant step up in business with Switzerland's Marionnaud.
The step change after this is even more dramatic, with the skincare group predicting its revenues for the 12 months ended March 31, 2026.
The news came via a trading statement in which investors were told an initial order of Skin + CELL products from Marionnaud had been doubled to 50,000, generating initial sales of £2 million.
Further momentum is anticipated with a second order of 250,000 units, aimed at meeting the high demand forecasted for the European launch and the initial phase of the Asian rollout in Q1 2025.
This scale-up is projected to enhance gross margin and net revenue significantly for Incanthera, thanks to expected economies of scale.
"The immediate doubling of our first manufacturing batch is a fantastic endorsement of our product range and demonstrates the high confidence and anticipation with which we are preparing for Skin + CELL's promotional launch on the shelves of Marionnaud's European stores," said Incanthera chairman Tim McCarthy.
The company also announced the launch of a fifth product - an eye serum.
The news will have a knock-on boost for ImmuPharma PLC (AIM:IMM), which still holds a 10.8% stake in Incanthera.